euglena Co., Ltd.
333.00
JPY
0.00
(0.00%)
ISIN
JP3944370000
Return %
Stock
S&P 500
1Y
-25.17
14.20
3Y
-54.32
81.12
5Y
-60.55
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Tomohiro Wakahara
- Full Time Employees
- 793
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- G-BASE Tamachi Tokyo TY Japan 108-0014
- IPO Date
- Dec 12, 2012
- Website
- euglena.jp
- Similar Companies
- Business
- Euglena Co., Ltd. is a Japan-based biotechnology company specializing in the research, development, production, and sale of microalgae-derived products. Its core offerings include functional foods and supplements; cosmetics leveraging the unique properties of Euglena algae for skin health; and biofuels such as Sustainable Aviation Fuel (SAF) and Hydrotreated Vegetable Oil (HVO). The company operates through three main business segments: Healthcare, which focuses on planning and sales of food products and cosmetics using their proprietary microalgae cultivation; Biofuel, which is engaged in the development, production, and commercialization of next-generation biofuels and cultivation technology; and Other Businesses, including organic compound fertilizers, genetic analysis services, and agritech innovations. Euglena’s manufacturing base includes a production plant on Ishigaki Island, Okinawa, known for sustainable and nature-rich conditions. Founded in 2005 and headquartered in Minato-ku, Tokyo, Euglena continues to drive innovation in sustainable bio-product development. The company recently expanded its biofuel operations by increasing its equity stake to 15% in a Malaysian biorefinery joint venture alongside PETRONAS and Eni, targeting an annual handling capacity of approximately 100,000 kiloliters of biofuels, including SAF and HVO. This milestone advances Euglena toward commercialization expected by late 2028, with projected revenue of JPY 30 billion and significant profit contributions. Additionally, Euglena secured a joint research agreement with PETRONAS Research Sdn. Bhd. and demonstrated successful high-density tank cultivation scaling. In 2024, the company reported improved financial performance marked by a 2.4% increase in net sales and substantial EBITDA growth reflecting stronger cash flow management. Euglena’s strategy emphasizes sustainability and innovation to address nutritional, environmental, and energy challenges across Japan and globally in partnership with leading energy and biotech firms.